NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Replimune Group, Inc. (REPL) Stock Analysis

Replimune Group, Inc. (REPL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

REPL

$15.04

−$0.25 (−1.64%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare REPL with… →

REPL Key Statistics

As of Sep 4, 2026
Trading
Open
$15.22
Previous Close
$15.29
Day's Range
14.80–15.33
52-Week Range
1.50–16.33
Volume
908.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.94
Valuation
Market Cap
$1.42B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.15
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$313.94M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
94.22M
1-Year Return
+158.86%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
4.56M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

REPL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+54.73%
2025−19.74%
2024+43.65%
2023−69.01%
2022+0.37%
2021−28.96%
2020+165.85%
2019+43.50%
2018 (partial year)−34.04%

As of September 4, 2026.

REPL Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$313.94M—
2024$0.00−$247.30M—
2023$0.00−$215.79M—
2022$0.00−$174.28M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$318.32M−$313.94M—
2024$0.00—−$259.85M−$247.30M—
2023$0.00—−$232.85M−$215.79M—
2022$0.00—−$174.17M−$174.28M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

REPL Valuation vs Biotechnology Median

Median of 656 stocks
MetricREPLBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Replimune Group, Inc. (REPL) at $1.42B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 465.

REPL last closed at $15.04 on September 4, 2026. That is −$0.25 (−1.64%) against the previous close. Over the past 52 weeks the price has ranged from $1.50 to $16.33. The latest close sits 902.67% above that 52-week low.

Financial Health

In fiscal 2025, Replimune Group, Inc. reported revenue of $0.00. The same year closed with a net loss of $313.94M. The reported profit margin is 0%. Trailing earnings per share are −3.15.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.94. Daily returns over the trailing 8 years annualize to a volatility of 115.12%. Over the trailing twelve months the price has returned +158.86%. Measured over 5 years, that is −14.51% a year compounded.

Growth & Income

The record shows no dividend for REPL.

2026 is still running; the price is +54.73% year to date. Across the complete calendar years on file, 2020 returned +165.85% and 2023 returned −69.01%. Of the 7 complete calendar years on file, 4 finished higher.

Peer Comparison

Replimune Group, Inc. (REPL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Replimune Group, Inc. REPL $1.42B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Replimune Group, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Replimune Group, Inc.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

Visit website →